Senescent cells secrete a combination of factors collectively known as the senescence-associated secretory phenotype (SASP). The SASP reinforces senescence and activates an immune surveillance response, but it can also show pro-tumorigenic properties and contribute to age-related pathologies. In a drug screen to find new SASP regulators, we uncovered the mTOR inhibitor rapamycin as a potent SASP suppressor. Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2 (also known as MAPKAPK2) kinase through 4EBP1. In turn, MAPKAPK2 phosphorylates the RNA-binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous SASP components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells in both tumour-suppressive and tumour-promoting contexts. Altogether, our results place regulation of the SASP as a key mechanism by which mTOR could influence cancer, age-related diseases and immune responses.
|Number of pages||13|
|Journal||Nature Cell Biology|
|Early online date||17 Aug 2015|
|Publication status||Published - Sep 2015|
FingerprintDive into the research topics of 'mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype'. Together they form a unique fingerprint.
- Deanery of Molecular, Genetic and Population Health Sciences - Visitor: Staff Non UK HEI
Person: Affiliated Independent Researcher